Abstracts tagged "ANCA"

Abstract Number: 1945 • 2016 ACR/ARHP Annual Meeting
Development and Validation of Case-Finding Algorithms for the Identification of Patients with ANCA-Associated Vasculitis and Large-Vessel Vasculitis in Healthcare Administrative Databases
Antoine G. Sreih¹, Narender Annapureddy², Jason Springer³, Kevin Byram⁴, George Casey⁵, Andy Cruz⁶, Maya Estephan⁷, Vince Frangiosa⁸, Michael D. George⁸, Mei Liu⁹, Mehrdad Maz¹⁰, Adam Parker⁷, Sapna Sangani¹¹, Rebecca Sharim¹² and Peter A. Merkel¹³, ¹Rheumatology, The University of Pennsylvania, Philadelphia, PA, ²Vanderbilt University, Nashville, TN, ³Department of Internal Medicine, Division of Allergy, Clinical Immunology, & Rheumatology, Kansas University Medical Center, Kansas City, KS, ⁴Internal Medicine, Vanderbilt University, Nashville, TN, ⁵The Vasculitis Foundation, Kansas City, MO, ⁶Informational Technology, The University of Pennsylvania, Philadelphia, PA, ⁷Rheumatology, The University of Kansas, Kansas City, KS, ⁸Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Informational Technology, The University of Kansas, Kansas City, KS, ¹⁰Allergy, Clinical Immunology, and Rheumatology, The University of Kansas Medical Center, Department of Internal Medicine, Division of Allergy, Clinical Immunology and Rheumatology, Kansas City, KS, ¹¹Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹²Rheumatology, Temple University, Philadelphia, PA, ¹³Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: ANCA-associated vasculitis (AAV) is a group of vasculitides that consists of granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (Churg-Strauss; EGPA), and microscopic polyangiitis…
Abstract Number: 881 • 2015 ACR/ARHP Annual Meeting
ANCA Associated Vasculitis with Hypocomplementemia Has More Diffuse Alveolar Hemorrhage and a Poor Prognosis
Shoichi Fukui¹, Naoki Iwamoto², Masataka Umeda², Ayako Nishino², Yoshikazu Nakashima², Tomohiro Koga², Shin-ya Kawashiri², Kunihiro Ichinose², Yasuko Hirai¹, Mami Tamai³, Hideki Nakamura¹, Tomoki Origuchi⁴ and Atsushi Kawakami¹, ¹Nagasaki University, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ³Transitional Med/Immun/Rheum, Nagasaki University, Nagasaki, Japan, ⁴Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan
Background/Purpose: ANCA associated vasculitis (AAV) is known as a systemic vasculitis with unknown etiology. Recently, relationship between AAV and complement have been shown and complement…
Abstract Number: 884 • 2015 ACR/ARHP Annual Meeting
Patient Perceptions of Treatment with Glucocorticoids in ANCA-Associated Vasculitis
Joanna Robson¹, Susan Ashdown², Jill Dawson³, Ebony Easley⁴, Don Gebhart⁵, Katherine Kellom⁶, Georgia Lanier⁷, Nataliya Milman⁸, Jacqueline Peck⁹, Judy A. Shea¹⁰, Peter F. Cronholm⁴ and Peter A. Merkel¹¹, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ²NONE, Branbury, United Kingdom, ³Nuffield Department of Population Health HSRU, University of Oxford, Oxford, United Kingdom, ⁴Department of Family Medicine and Community Health, The University of Pennsylvania, Philadelphia, PA, ⁵NONE, Columbus, OH, ⁶PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, United Kingdom, ⁷NONE, Framingham, MA, ⁸Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ⁹NONE, Oxford, United Kingdom, ¹⁰Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, United Kingdom, ¹¹Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA) comprise a group of multisystem diseases of the small blood vessels…
Abstract Number: 886 • 2015 ACR/ARHP Annual Meeting
Rituximab As a Cyclophosphimide Sparing Agent for Patients with Multi-Relapsing Antineutrophil Cytoplasmic Antibody Associated Small Vessel Vasculitis
Sophia Lionaki¹, George Fragoulis², Aliki Venetsanopoulou², Panayiotis Vlachoyiannopoulos², John Boletis¹, Haralampos M. Moutsopoulos² and Athanasios G. Tzioufas², ¹Nephrology, Laiko Hospital, Department of Nephrology, Athens, Greece, ²Pathophysiology, School of Medicine, National University of Athens, Athens, Greece
Background/Purpose: To evaluate the long term outcomes, of patients with multi-relapsing Antineutrophil Cytoplasmic Antibody (ANCA) associated Vasculitis (AAV), who received induction therapy with a rituximab…
Abstract Number: 887 • 2015 ACR/ARHP Annual Meeting
Intravenous Immunoglobulin As Immunomodulating Agent in ANCA-Associated Vasculitides: A French Nationwide Study of 92 Patients
Etienne Crickx¹, Irène Machelart², Estibaliz Lazaro³, Jean-Emmanuel Kahn⁴, Fleur Cohen⁵, Thierry Martin⁶, Alexandre Mania⁷, Pierre-Yves Hatron⁸, Gilles Hayem⁹, Claire Blanchard-Delaunay¹⁰, Claire De Moreuil¹¹, Guillaume Le Guenno¹², Frédéric Vandergheynst¹³, Francois Maurier¹⁴, Bruno Crestani¹⁵, Robin Dhote¹⁶, Nicolas Martin Silva¹⁷, Yann Ollivier¹⁸, Anas Mehdaoui¹⁹, Bertrand Godeau²⁰, Xavier Mariette²¹, Jacques Cadranel²², Pascal Cohen²³, Xavier Puéchal²³, Claire Le Jeunne²⁴, Luc Mouthon²⁵, Loïc Guillevin²⁶ and Benjamin Terrier²³, ¹Internal Medicine, Cochin Hospital, Paris, France, ²Hôpital Pellegrin, Pessac, France, ³Hôpital Haut-Lévêque, Pessac, France, ⁴Internal Medicine, Foch Hospital, Suresnes, France, ⁵Internal Medicine Dpt 2, Pitié-Salpêtrière Hospital, APHP, Paris, France, ⁶Cnrs UPR9021, IBMC, Strasbourg, France, ⁷Hôpital Gabriel Montpied, Clermont-Ferrand, France, ⁸Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, ⁹Hôpital Ambroise Paré, Boulogne Billancourt, France, ¹⁰Internal Medicine, Centre Hospitalier, Niort, France, ¹¹CHU, Brest, France, ¹²Internal Medicine department, Clermont-Ferrand, France, ¹³Hôpital Erasme, Bruxelles, Belgium, ¹⁴HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ¹⁵Pneumology, Bichat Claude-bernard, Universitary Hospital, APHP, Paris, France, ¹⁶Internal Medicine, Hospital Avicenne, Bobigny, France, ¹⁷CHU Caen, caen, France, ¹⁸Hôpital Cote de Nacre, Caen, France, ¹⁹Hôpital Eure Seine, Evreux, France, ²⁰Henri Mondor, Créteil, France, ²¹Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ²²Hôpital Tenon, Paris, France, ²³Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ²⁴Department of Internal Medicine, Hotel-Dieu Hospital, AP-HP, Paris, Paris, France, ²⁵Department of Internal Medicine, Department of Internal Medicine, Cochin Hospital, Referent Center for Necrotizing Vasculitis and Systemic Sclerosis, Paris-Descartes University, AP-HP, Paris, France, ²⁶Internal Medicine, Hopital Cochin, Paris, France
Background/Purpose: Despite recent therapeutic advances in treating ANCA-associated vasculitides (AAVs), some patients relapse or require long-term immunosuppression, leading to significant morbidity and mortality. IVIg represents…
Abstract Number: 888 • 2015 ACR/ARHP Annual Meeting
Plasma Exchanges to Treat Primary Systemic Necrotizing Vasculitides: Data from a French Nationwide Study
Gonzalo De Luna¹, Dominique Chauveau², Julien Aniort³, Pierre-Louis Carron⁴, Pierre Gobert⁵, Alexandre Karras⁶, Sylvain Adam-Marchand⁷, Francois Maurier⁸, Pierre-Yves Hatron⁹, Alexandre Mania¹⁰, Guillaume Le Guenno¹¹, Stéphane Ballly¹², Boris Bienvenu¹³, Eric Cardineau¹⁴, Tiphaine Goulenok¹⁵, Noémie Jourde-Chiche Sr.¹⁶, Maxime Samson¹⁷, Antoine Huart¹⁸, Jacques Pourrat¹⁹, Aurelien Tiple²⁰, Olivier Aumaître²¹, Xavier Puéchal²², Farhad Heshmati²³, Claire Le Jeunne²⁴, Luc Mouthon²⁵, Loïc Guillevin²⁶ and Benjamin Terrier²², ¹Medecine Interne, Cochin University Hospital, Paris, France, ²CH Toulouse, Toulouse, France, ³CHU, Clermont-Ferrand, France, ⁴Internal Medicine, Centre Hospitalier de Grenoble, Grenoble, France, ⁵Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ⁶George Pompidou European Hospital, Paris, France, ⁷Pneumology, Centre Hospitalier Universitaire de Tours, Tours, France, ⁸HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁹Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, ¹⁰Hôpital Gabriel Montpied, Clermont-Ferrand, France, ¹¹Internal Medicine department, Clermont-Ferrand, France, ¹²CH, Chambéry, France, ¹³Internal Medicine, Hospital Caen, Caen, France, ¹⁴CH, Alencon, France, ¹⁵University Paris Diderot - APHP - Bichat Hospital, aris, France, ¹⁶Nephrology, Aix-Marseille Université - APHM, Marseille, France, ¹⁷Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ¹⁸CHU, Toulouse, France, ¹⁹Nephrology, Rangeuil Hospital, Paris, France, ²⁰Nephrology, CHU, Clermont-Ferrand, France, ²¹Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ²²Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ²³Cochin Hospital, Paris, France, ²⁴Department of Internal Medicine, Hotel-Dieu Hospital, AP-HP, Paris, Paris, France, ²⁵Department of Internal Medicine, Department of Internal Medicine, Cochin Hospital, Referent Center for Necrotizing Vasculitis and Systemic Sclerosis, Paris-Descartes University, AP-HP, Paris, France, ²⁶Internal Medicine, Hopital Cochin, Paris, France
Background/Purpose: Plasma exchange (PE) is usually used to treat severe primary systemic necrotizing vasculitides (SNVs) and/or virus-induced vasculitides. Only severe renal insufficiency (serum creatinine (SCR)…
Abstract Number: 892 • 2015 ACR/ARHP Annual Meeting
Autoimmune Associated Orbital Inflammatory Masses and Response to Immunosuppressive Therapy
Alina Casian¹, Shirish Sangle (joint first author)², Ritu Malaiya³, Pamela Lutalo⁴, Louise Nel⁵, Bina Menon⁶, Hema Varma⁷, Miles Stanford⁸ and David P. D'Cruz⁵, ¹Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, UK, London, United Kingdom, ²Louise Coote Lupus Unit, Guy's and St. Thomas' Hospital, London, United Kingdom, ³Louise Coote Lupus Unit, Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom, ⁴Rheumatology, St. George's Hospital, London, United Kingdom, ⁵Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom, ⁶Rheumatology, Guy's Hospital, London, United Kingdom, ⁷Radiology, Guy's and St. Thomas' Hospital, London, United Kingdom, ⁸Ophthalmology, Guy's and St. Thomas' Hospital, London, United Kingdom
Background/Purpose: To characterize a single centre retrospective case series of patients with orbital inflammatory masses associated with autoimmune diseases including granulomatosis with polyangiitis(GPA)(formerly Wegener’s granulomatosis),…
Abstract Number: 1082 • 2015 ACR/ARHP Annual Meeting
ANCA-Negative and Myeloperoxidase-ANCA-Positive Patients with Granulomatosis with Polyangiitis: Clinical Manifestations and Risk of Relapse
Eli Miloslavsky¹, Na Lu², Sebastian Unizony³, Hyon K. Choi³, Peter A. Merkel⁴, Philip Seo⁵, Robert F. Spiera⁶, Carol A. Langford⁷, Gary S. Hoffman⁷, Cees Kallenberg⁸, E. William St.Clair⁹, Nadia Tchao¹⁰, Fernando Fervenza¹¹, Paul A. Monach¹², Ulrich Specks¹³ and John H. Stone¹⁴, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵Division of Rheumatology, Johns Hopkins, Baltimore, MD, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Rheumatology, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology/Clin Immunol AA21, Univer Med Center Groningen, Groningen, Netherlands, ⁹Rheumatology and Immunology, Duke University, Durham, NC, ¹⁰ITN, San Francisco, CA, ¹¹Mayo Clinic, Rochester, MN, ¹²Rheumatology, Boston University School of Medicine, Boston, MA, ¹³Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN, ¹⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Recent studies in ANCA-associated vasculitis (AAV) have suggested that classification based on ANCA type (PR3 versus MPO) may represent a more clinically relevant division…
Abstract Number: 1083 • 2015 ACR/ARHP Annual Meeting
Nationwide Trends in Hospitalization and in-Hospital Mortality Associated with Granulomatosis with Polyangiitis (GPA)
Zachary Wallace¹, John H. Stone², Hyon K. Choi³, Na Lu³, Sebastian Unizony³ and Eli Miloslavsky⁴, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ³Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Massachusetts General Hopsital, Boston, MA
Background/Purpose: Granulomatosis with polyangiitis (GPA) is associated with severe end-organ damage (e.g., renal failure) and treatment-related complications (e.g., severe infection) which often lead to hospitalization…
Abstract Number: 856 • 2015 ACR/ARHP Annual Meeting
Elderly Versus Younger Patients with ANCA-Associated Vasculitis
Maria de los Angeles Gallardo¹, Marina Scolnik¹, Luciano Enrique Pompermayer¹, Valeria Scaglioni² and Enrique R. Soriano³, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Rheumatology, Hospital Italiano, Buenos Aires, Argentina, ³Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Clinical characteristics of elderly patients with ANCA- associated vasculitis (AAV) have not been fully elucidated. Advancing age is a risk factor for treatment-related side effects…
Abstract Number: 1084 • 2015 ACR/ARHP Annual Meeting
Improved Survival in Granulomatosis with Polyangiitis: A General Population-Based Study
Zachary Wallace¹, Sebastian Unizony², Na Lu², Hyon K. Choi² and John H. Stone³, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Granulomatosis with polyangiitis (GPA) is associated with an increased risk of mortality. Advances in diagnosis and treatment strategies are thought to improve outcomes in…
Abstract Number: 858 • 2015 ACR/ARHP Annual Meeting
Stimulated Renal Glomerular Endothelial Cells Were Damaged By Fiber-like NETs Released By Neutrophils in ANCA-Associated Vasculitis
Yoshinori Komagata¹, Kanako Murakami¹, Chimako Kida¹, Kazuhito Fukuoka¹, Miho Karube², Shinya Kaname¹ and Yoshihiro Arimura¹, ¹First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ²Kyorin University School of Medicine, Tokyo, Japan
Background/Purpose: NETosis, a unique form of cell death of neutrophils, is characterized by the active release of chromatin fibers called NETs, that trap and kill…
Abstract Number: 2415 • 2015 ACR/ARHP Annual Meeting
Use of Plasma Exchange for Children Hospitalized with ANCA-Associated Vasculitis in the United States
Karen James¹, Rui Xiao², Peter A. Merkel³ and Pamela F. Weiss¹, ¹Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: ANCA-associated vasculitis (AAV) is a group of rare systemic vasculitidies with significant morbidity and mortality. Plasma exchange (PLEX) has been shown to decrease risk…
Abstract Number: 859 • 2015 ACR/ARHP Annual Meeting
Predictors of Renal Histopathology in Antineutrophil Cytoplasmic Antibody Associated Glomerulonephritis
Sophia Lionaki¹, Clio Mavragani², George Liapis³, George Somarakis⁴, John Boletis¹, Alexandros A. Drosos⁵, Athanasios G. Tzioufas⁶ and Haralampos M. Moutsopoulos⁶, ¹Nephrology, Laiko Hospital, Department of Nephrology, Athens, Greece, ²Physiology, Department of Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece, ³Pathology, Laiko Hospital, Department of Pathology, Athens, Greece, ⁴Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, University of Ioannina, Rheumatology Clinic, Ioannina, Greece, ⁵Dept of Internal Medicine, University of Ioannina, Rheumatology Clinic, Ioannina, Greece, ⁶Department of Pathophysiology, Medical School of Athens, Department of Pathophysiology, Athens, Greece
Background/Purpose: Prompt, aggressive therapy is vital for anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (GN). In this regard, we aimed to identify predictors of distinct renal histopathological…
Abstract Number: 861 • 2015 ACR/ARHP Annual Meeting
ANCA-Associated Pauci-Immune Glomerulonephritis: ¿Always Pauci-Immune?
Valeria Scaglioni¹, Marina Scolnik¹, Luis J. Catoggio¹, Carlos Federico Varela², Gustavo Greloni², Silvia Christiansen³ and Enrique R. Soriano⁴, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Nephrology Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Pathology Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Internal Medicine, Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (GN) is considered a “pauci-immune” disease, characterized by absent or mild glomerular tuft staining for immunoglobulin and/or complement. However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].